

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|--|--|---|---|
| Drugs to Treat High Cholesterol | | | |
| Statins | HMG CoA Reductase Inhibitors - ↓ Cholesterol Synthesis - ↑ Hepatic LDL Receptors | - ↓ LDL Cholesterol - ↑ HDL Cholesterol - ↓ Triglycerides | -Myopathy (most common) -Rhabdomyolysis -Hepatotoxicity |
| Ezetimibe | A cholesterol absorption inhibitor -Inhibit the intestinal transport protein NPC1L1 | - ↓ Intestinal cholesterol absorption | -Hepatotoxicity -Myopathy |
| Nicotinic Acid | -Inhibits secretion of VLDL | - ↓ Triglycerides - ↓ LDL Cholesterol - ↑ HDL Cholesterol | -Facial flushing -Hepatotoxicity -Hyperglycemia -Skin rash - ↑ Uric acid levels |
| Cholesterol Absorption Inhibitors | -Inhibit the intestinal transport protein NPC1L1 | - ↓ Intestinal cholesterol absorption | -Hepatotoxicity -Myopathy |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|------------------------------------|--|--|---|
| Fibric Acid Derivatives (Fibrates) | -Activate hepatic PPAR α receptor -PPAR α receptor activation causes: - \uparrow Lipoprotein lipase - \downarrow Apolipoprotein C-III - \uparrow Apolipoprotein A-I & A-II | - \downarrow Triglycerides - \uparrow HDL cholesterol | -Risk of gall stones -Myopathy -Hepatotoxicity |
| Bile Acid Sequestrants | -Bind bile acids and prevent their absorption | - \uparrow Hepatic LDL receptors - \downarrow LDL Cholesterol | -Constipation -Bloating -Decreased absorption of negatively charged drugs |
| Vytorin | -A combination of simvastatin & ezetimibe | | |
| Drugs to Treat Hypertension | | | |
| Loop Diuretics | -Block Na and Cl ion reabsorption in the thick ascending limb of the loop of Henle | - \downarrow total body water - \downarrow peripheral vascular resistance | -Hypokalemia -Hyponatremia -Dehydration -Hypotension |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|---|---|---|--|
| Thiazide Diuretics | -Block Na and Cl ion reabsorption in the distal tubule | - ↓ total body water - ↓ peripheral vascular resistance | -Hypokalemia (major side effect) -Hyponatremia -Dehydration |
| Potassium Sparing Diuretics/Aldosterone Antagonists | -Blocks aldosterone receptors | - ↓ renal K excretion -minimal diuresis | -Hyperkalemia |
| Beta Blockers | -Inhibit beta 1 adrenergic receptors in the heart and juxtaglomerular cells in the kidney | -Heart: ↓ CO by ↓ contractility and HR -Kidney: ↓ renin secretion which decreases angiotensin II mediated vasoconstriction and aldosterone mediated volume expansion | -Bradycardia - ↓ CO -Heart failure (rare) -Rebound hypertension/ cardiac excitation |
| Direct Renin Inhibitors | -Inhibit plasma renin with high affinity | -Inhibits conversion of angiotensinogen to angiotensin I, therefore ↓ concentrations of angiotensin I, angiotensin II and aldosterone leading to ↓ BP | -Hyperkalemia -Cough -Diarrhea |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|---|--|--|--|
| Angiotensin Converting Enzyme Inhibitors (ACEI) | -Inhibit angiotensin converting enzyme (ACE) | -Blocks conversion of angiotensin I to angiotensin II and aldosterone which leads to ↓ BP | <ul style="list-style-type: none"> -1st dose hypotension -Rash -Chronic cough -Hyperkalemia -Angioedema |
| Angiotensin Receptor Blockers (ARBs) | -Inhibit the angiotensin I receptor (AT1) with high affinity | <ul style="list-style-type: none"> -Relaxation of smooth muscle - ↓ peripheral resistance and therefore ↓ BP -Causes ↓ secretion of aldosterone | <ul style="list-style-type: none"> -Unlike ACEIs, ARBs do not cause chronic cough -Very low incidence of angioedema |
| Dihydropyridine Calcium Channel Blockers | -Block Ca channels in arterial smooth muscle cells | -Peripheral and coronary vasodilation which causes ↓ peripheral resistance and therefore ↓ BP | <ul style="list-style-type: none"> -Reflex tachycardia -Edema -Dizziness -Flushing -Headache -Rash |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|--|---|---|---|
| Non-dihydropyridine Calcium Channel Blockers | -Block Ca channels in arterial smooth muscle cells and cardiac muscle cells | -Peripheral and coronary vasodilation which causes ↓ peripheral resistance and therefore ↓ BP -Blockade in cardiac cells causes ↓ CO (mediated by ↓ HR, conduction velocity and contractility), therefore causing ↓ BP | -Constipation -Dizziness -Flushing -Headache -Edema -Compromised cardiac function |
| Alpha-2 Receptor Agonist | -Bind to alpha 2 receptors in the brainstem to cause ↓ sympathetic outflow | - ↓ CO and ↓ TPR | -Drowsiness -Dry mouth -Rebound hypertension if withdrawn abruptly |
| CNS I Drugs | | | |
| Levodopa | -Dopamine replacement, metabolized by decarboxylases to dopamine | - ↓ symptoms of Parkinson's disease | -Nausea/vomiting -Dyskinesias -Cardiac dysrhythmias -Orthostatic hypotension -Psychosis |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|--------------------|--|--|--|
| Dopamine Agonist | <ul style="list-style-type: none"> -Bind to and activate dopamine receptors in the brain | <ul style="list-style-type: none"> -Relieves mild symptoms of Parkinson's disease | <ul style="list-style-type: none"> -Hallucinations -Daytime drowsiness -Orthostatic hypotension |
| Dopamine Releasers | <ul style="list-style-type: none"> -Stimulate the release of dopamine from dopaminergic neurons -Inhibit dopamine re-uptake -Block NMDA receptors | <ul style="list-style-type: none"> -Effective treatment of mild Parkinson's, often combined with L-Dopa | <ul style="list-style-type: none"> -Dizziness -Nausea/Vomiting -Lethargy -Anticholinergic side effects |
| COMT Inhibitors | <ul style="list-style-type: none"> -Inhibit metabolism of dopamine and L-Dopa | <ul style="list-style-type: none"> -Allows greater conversion of L-Dopa to dopamine and increases brain dopamine levels -Only moderately effective at treating Parkinson's Disease, therefore often combined with L-Dopa | <ul style="list-style-type: none"> -Nausea -Orthostatic hypotension -Vivid dreams -Hallucinations |
| MAO-B Inhibitors | <ul style="list-style-type: none"> -Inhibit the metabolism of L-Dopa and dopamine | <ul style="list-style-type: none"> - ↑ brain levels of L-Dopa and dopamine -Moderately effective in treating Parkinson's, often combined with L-Dopa | <ul style="list-style-type: none"> -Insomnia -Orthostatic hypotension -Dizziness |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|-----------------------------|--|--|--|
| Anticholinergic Drugs | -Block the binding of acetylcholine to its receptor | - ↓ some symptoms of Parkinson's | <ul style="list-style-type: none"> -Dry mouth -Blurred vision -Urinary retention -Constipation -Tachycardia |
| Cholinesterase Inhibitors | -Inhibit the metabolism of acetylcholine by blocking the enzyme acetylcholinesterase | - ↑ brain levels of acetylcholine, used to treat symptoms of Alzheimer's | <ul style="list-style-type: none"> -Nausea/vomiting -Diarrhea -Insomnia |
| NMDA Receptor Antagonists | -Block Ca entry into post-synaptic neurons | -Inhibits degradation of cholinergic neurons (only mildly effective) | -Well tolerated |
| Conventional Antipsychotics | -Dopamine 2 receptor antagonists | - ↓ positive symptoms of schizophrenia | <ul style="list-style-type: none"> -Extrapyramidal symptoms -Sudden high fever -Anticholinergic effects -Orthostatic hypotension -Sedation -Skin reactions |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|---------------------------------------|---|---|---|
| Atypical Antipsychotics | <ul style="list-style-type: none"> -Block 5-HT_{1A} receptors -Block 5-HT_{2A} receptors -Block D₂ receptors (low affinity for D₂ receptors) | -Effective against positive and negative symptoms of schizophrenia | <ul style="list-style-type: none"> -Sedation -Orthostatic hypotension -Weight gain (sometime severe) -Risk of developing type II diabetes -Anticholinergic effects |
| CNS II Drugs | | | |
| Phenytoin | <ul style="list-style-type: none"> -Blocks Na channels-> ↓ spontaneous depolarizations -Non-linear pharmacokinetics | <ul style="list-style-type: none"> -Treats all types of seizures except absence seizures -Traditional AED | <ul style="list-style-type: none"> -Sedation -Gingival hyperplasia -Skin rash -Teratogenic |
| Voltage Dependent Ca Channel Blockers | -block voltage dependent calcium channels -> ↓ neurotransmitter release | -Effective in treating epileptic seizures | N/A |
| Glutamate Antagonists | -blocks action of glutamate(ExNT) at NMDA-R and AMPA-R | -Effective in treatment of seizures | N/A |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|---|--|---|--|
| Valproic Acid | N/A | <ul style="list-style-type: none"> -Traditional AED -Mood stabilizer in treatment of bipolar disorder | N/A |
| Lamotrigine | N/A | <ul style="list-style-type: none"> -Newer class of AED | <ul style="list-style-type: none"> -Decreased side effects compared to traditional AEDs |
| Tricyclic Antidepressants (TCAs) | <ul style="list-style-type: none"> -Inhibit the re-uptake of serotonin and norepinephrine | <ul style="list-style-type: none"> - ↓ symptoms of major depression -useful in treatment of panic disorder and agoraphobia | <ul style="list-style-type: none"> -Anticholinergic effects -Sedation -Orthostatic hypotension - ↓ Seizure threshold -Weight gain -Sexual dysfunction -Cardiac toxicity(rare) |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | <ul style="list-style-type: none"> -block reuptake of serotonin | <ul style="list-style-type: none"> -Effective treatment of depression(especially major depression) -effective in treating generalized anxiety disorder, panic disorder, agoraphobia, OCD, social anxiety disorder | <ul style="list-style-type: none"> -Weight gain -Sexual dysfunction -Insomnia -Serotonin syndrome |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|--|--|--|---|
| Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) | -Inhibit the reuptake of serotonin | -Effective treatment of major depression -Also effective in treating generalized anxiety disorder | -Nausea -Diastolic hypotension -Sexual dysfunction |
| MAO Inhibitors | -Inhibit the metabolism of serotonin and norepinephrine | -Effective in treatment of atypical depression and dysthymia | -CNS excitation(anxiety, insomnia, agitation) -Orthostatic hypotension -Hypertensive crisis if taken with tyramine containing foods |
| Lithium | -alter uptake and release of glutamate -blocks the binding of glutamate | -Mood stabilizer used in treatment of bipolar disorder | -GI upset -Tremor -Sedation -Hypotension |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|----------------------------|--|--|---|
| Benzodiazepines | -bind to GABA receptor and allow greater binding of GABA to receptor -> ↑ | -effective treatment of anxiety, epileptic seizures, insomnia, alcohol withdrawal and muscle spasm | -CNS depression(drowsiness) -Anterograde amnesia -Respiratory depression -Teratogenic -Tolerance (to anti-seizure effects, but not for anxiolytic or sedative effects) -Withdrawal |
| Buspirone | -Modulation of serotonin and dopamine neurotransmission | -effective treatment of generalized anxiety disorder | -Dizziness -Lightheadedness -Excitement |
| Diabetes Drugs | | | |
| Insulin(Metabolic Actions) | <ul style="list-style-type: none"> - ↑ Cellular uptake of glucose into liver, muscle & fat - ↑ Cellular uptake of amino acids - ↓ Hepatic gluconeogenesis | - ↓ Blood glucose | -Hypoglycemia (tachycardia, palpitations, sweating, nervousness, headache, confusion, drowsiness, fatigue) |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|--------------------------|--|--|-----------------|
| Insulin Lispro | -Short duration, rapid acting insulin | -Used to control postprandial rise in glucose | |
| Insulin Aspart | -Short duration, rapid acting insulin | -Used to control postprandial rise in glucose | |
| Insulin Glulisine | -Short duration, rapid acting insulin | -Used to control postprandial rise in glucose | |
| Unmodified Human Insulin | -Short duration, slower acting insulin | -Used to control postprandial rise in glucose | |
| NPH Insulin | -Intermediate duration insulin -Supplied as a cloudy suspension | -Used to control blood glucose between meals and in the evenings | |
| Insulin Detemir | -Intermediate duration insulin | -Used to control blood glucose between meals and in the evenings | |
| Insulin Glargine | -Long duration insulin | -Administered once daily to control blood glucose levels | |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|---------------------------------|--|-----------------------|---|
| Glucagon | -Causes glycogenolysis | - ↑ Blood glucose | -Hyperglycemia |
| Biguanides | - ↑ Sensitivity and number of insulin receptors - ↓ Hepatic gluconeogenesis - ↓ Glucose absorption | -Lowers blood glucose | -Nausea -Decreased appetite -Diarrhea - ↓ Absorption of vitamin B12 and folic acid -Lactic Acidosis |
| Sulfonylureas | -Stimulate release of insulin from the pancreas -Inhibit glycogenolysis | -Lowers blood glucose | -Hyperglycemia -Pancreatic burnout |
| Meglitinides | -Stimulate insulin release from the pancreas | -Lowers blood glucose | -Hyperglycemia -Pancreatic burnout *both less likely than with sulfonylureas |
| Thiazolidinediones (Glitazones) | -Activates the PPAR γ receptor which causes ↑ number of glucose receptors | -Lowers blood glucose | -Fluid retention/edema -Headache -Myalgia |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|------------------------------|--|--|---|
| Alpha Glucosidase Inhibitors | -Inhibits the metabolism of complex carbohydrates by inhibiting the enzyme alpha-glucosidase | - ↓ Intestinal glucose absorption, therefore lowers blood glucose | -Flatulence -Cramps -Abdominal distention -Diarrhea - ↓ Iron absorption |
| Gliptins | -Inhibit the enzyme dipeptidyl peptidase (DPP-4) | - ↑ Levels of GLP-1 & GIP and therefore ↑ insulin release, ↓ glucagon release -Net effect is lowering glucose | -N/A |
| Incretin Mimetics | -Mimic the actions of incretin hormones by binding to and activating incretin receptors | - ↑ Insulin release - ↓ Glucagon release -Net effect is decreased blood glucose | -Hyperglycemia -Pancreatitis |
| Antibiotics | | | |
| Penicillins | -Inhibit transpeptidases and activate autolysins | -Inhibit cell wall synthesis -Bactericidal | -Potential for allergic reaction |
| Cephalosporins | -Inhibit transpeptidases and activate autolysins | -Inhibit cell wall synthesis -Bactericidal | -Potential for allergic reaction |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|-----------------|---|---|--|
| Vancomycin | -Blocks the transglycosylation step in cross bridge synthesis | -Inhibit cell wall synthesis -Bactericidal | -Ototoxicity -Red person syndrome |
| Tetracyclines | -Bind to 30S ribosomal subunit to prevent addition of amino acids to the peptide chain | -Inhibit bacterial protein synthesis -Bacteriostatic | -GI Irritation -Photosensitivity -Superinfection |
| Macrolides | -Bind to 50S ribosomal subunit and therefore block the addition of amino acids to the peptide | -Inhibit bacterial protein synthesis -Bacteriostatic | -GI upset -QT interval prolongation |
| Oxazolidinones | -Bind to 50S ribosomal subunit and therefore block the addition of amino acids to the peptide | -Inhibit bacterial protein synthesis -Bacteriostatic | -Reversible myelosuppression |
| Aminoglycosides | -Bind to the 30S ribosomal subunit to prevent protein synthesis | -Inhibit bacterial protein synthesis -Bactericidal | -Ototoxicity -Nephrotoxicity |

| DRUG | MECHANISM OF ACTION | EFFECT | ADVERSE EFFECTS |
|-------------------------------|---|--|--|
| Sulfonamides/ Trimethoprim | -Inhibit bacterial folic acid synthesis | - ↓ Bacterial DNA synthesis -Bactericidal | -Fever -Photosensitivity -Stevens-Johnson syndrome |
| Fluoroquinolones | -Inhibits DNA gyrase and Topoisomerase IV | -Inhibits bacterial DNA replication -Bactericidal | -Nausea -Vomiting -Diarrhea |
| Isoniazid | -Inhibits mycolic acid synthesis | -Inhibits cell wall synthesis -Bactericidal | -Peripheral neuropathy -Hepatotoxicity |
| | | | |
| | | | |
| | | | |
| | | | |